Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 831 to 840 of 1090 total matches.
Dasiglucagon (Zegalogue) for Severe Hypoglycemia
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021 (Issue 1631)
and anaphylactic
shock, have been reported with glucagon.
DRUG INTERACTIONS — Patients taking beta
blockers ...
The FDA has approved dasiglucagon (Zegalogue –
Zealand) for subcutaneous (SC) treatment of severe
hypoglycemia in patients ≥6 years old with diabetes.
Dasiglucagon is the third glucagon product to be
marketed in the US that does not require reconstitution
before administration; Gvoke, a SC formulation approved for use in patients ≥2 years old, and Baqsimi,
an intranasal powder approved for use in patients
≥4 years old, have been available since 2019.
Injectable glucagon emergency kits (GlucaGen
HypoKit, and generics) have been available for years,
but they require...
Elacestrant (Orserdu) for Advanced or Metastatic Breast Cancer
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023 (Issue 1671)
). Disease
progression, which can be caused by drug resistance
due to ESR1 mutations, is often treated ...
The FDA has approved elacestrant (Orserdu –
Stemline), an oral estrogen receptor antagonist, for
treatment of estrogen receptor (ER)-positive, human
epidermal growth factor receptor 2 (HER2)-negative,
estrogen receptor 1 (ESR1)-mutated advanced or
metastatic breast cancer in postmenopausal women
or men who had disease progression following
endocrine therapy. Elacestrant is the first oral selective
estrogen receptor degrader (SERD) to be approved
for treatment of breast cancer; the injectable SERD
fulvestrant (Faslodex, and generics) was approved
more than 20 years...
Med Lett Drugs Ther. 2023 Mar 6;65(1671):38-40 doi:10.58347/tml.2023.1671d | Show Introduction Hide Introduction
CT Colonography (Virtual Colonoscopy) Revisited
The Medical Letter on Drugs and Therapeutics • Dec 01, 2008 (Issue 1300)
. Schwartz, M.D., Mount Sinai School of Medicine
DRUG INTERACTIONS FELLOW: Manouchkathe Cassagnol, Pharm.D ...
Options in screening for colon cancer include fecal occult blood tests, flexible sigmoidoscopy, colonoscopy, computed tomography (CT) colonography and fecal DNA tests. Since the last Medical Letter article on this subject, more data have become available on colonography.
CRP and Statins for Primary Prevention of Coronary Artery Disease
The Medical Letter on Drugs and Therapeutics • Dec 15, 2008 (Issue 1301)
EDITORIAL FELLOW: Lauren K. Schwartz, M.D., Mount Sinai School of Medicine
DRUG INTERACTIONS FELLOW ...
Modestly elevated C-reactive protein (CRP) concentrations have been associated with an increased risk of coronary heart disease. The recently published and heavily publicized results of the JUPITER trial will lead many patients to ask health care professionals whether they should have a CRP test to see if they should be taking a statin.
Vitamins for Cataract Prevention
The Medical Letter on Drugs and Therapeutics • Jun 16, 2008 (Issue 1288)
Letter
®
On Drugs and Therapeutics
Volume 50 (Issue 1288)
June 16, 2008
www.medicalletter.org ...
Cataracts are the leading cause of blindness worldwide because cataract surgery is not available to most people in developing countries.
Meropenem/Vaborbactam (Vabomere) for Complicated Urinary Tract Infection
The Medical Letter on Drugs and Therapeutics • Jun 18, 2018 (Issue 1549)
DRUG INTERACTIONS – Carbapenems can decrease
serum concentrations of valproate (Depakote,
Depakene ...
The FDA has approved a fixed-dose combination of
meropenem, a carbapenem antibiotic, and vaborbactam,
a new beta-lactamase inhibitor (Vabomere – Melinta),
for IV treatment of adults with complicated urinary
tract infections (UTIs) that are proven or strongly
suspected to be caused by Escherichia coli, Klebsiella
pneumoniae, or Enterobacter cloacae spp. complex.
Meropenem (Merrem, and generics) has been approved
for years for treatment of complicated skin and skin
structure infections, intra-abdominal infections, and
bacterial meningitis. Resistance to meropenem and
other...
Shingrix - An Adjuvanted, Recombinant Herpes Zoster Vaccine
The Medical Letter on Drugs and Therapeutics • Dec 04, 2017 (Issue 1535)
in the vaccine and placebo groups. Longterm
data on the safety of Shingrix are lacking.
DRUG INTERACTIONS ...
The FDA has approved an adjuvanted, recombinant
varicella zoster virus (VZV) vaccine (Shingrix – GSK)
for prevention of herpes zoster (shingles) in adults ≥50
years old. Shingrix is the second herpes zoster vaccine
to be approved in the US; Zostavax, a live-attenuated
VZV vaccine approved for the same indication, has been
available since 2006.
Brexpiprazole (Rexulti) for Agitation in Alzheimer's Dementia
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
an increased risk of death in older patients with
dementia-related psychosis.
DRUG INTERACTIONS ...
The FDA has approved the oral second-generation
antipsychotic drug brexpiprazole (Rexulti – Otsuka/Lundbeck) for once-daily treatment of agitation associated
with dementia due to Alzheimer's disease (AD).
Brexpiprazole is the first drug to be approved in the US
for this indication. It is also approved for treatment of
schizophrenia and as an adjunct to antidepressants for
treatment of major depressive disorder.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):99-101 doi:10.58347/tml.2023.1679b | Show Introduction Hide Introduction
Duloxetine (Cymbalta) for Diabetic Neuropathic Pain
The Medical Letter on Drugs and Therapeutics • Aug 15, 2005 (Issue 1215)
in pregnant or lactating women; it is not recommended for use in these patients.
DRUG INTERACTIONS ...
Duloxetine hydrochloride (Cymbalta - Lilly), a selective serotonin and norepinephrine reuptake inhibitor (SNRI) available for treatment of depression, has also been approved by the FDA for treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN). Duloxetine is one of two drugs approved specifically for management of neuropathic pain due to diabetes; the other, pregabalin (Lyrica - Pfizer), will be marketed soon and will be reviewed in the next issue of The Medical Letter.
Canagliflozin (Invokana) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 13, 2013 (Issue 1416)
during pregnancy.
DRUG INTERACTIONS — Canagliflozin is metabolized
primarily by UDP ...
Canagliflozin (kan" a gli floe' zin; Invokana – Janssen),
a sodium-glucose co-transporter 2 (SGLT2) inhibitor,
has been approved by the FDA for oral treatment of
type 2 diabetes.